Coherus Bioscien Stock Price, News & Analysis

Coherus Oncology (NASDAQ:CHRS) announced its participation in three upcoming investor conferences in September and October 2025. The company will present at the Baird 2025 Global Healthcare Conference on September 9, the H.C. Wainwright Global Investment Conference on September 10, and the UBS Virtual Oncology Day on October 1, 2025.

All presentations will be accessible through webcast links on the company's investor relations website, with replays available for 30 days. Investors interested in one-on-one meetings with management should contact their respective bank representatives.

Coherus Oncology (NASDAQ:CHRS) reported Q2 2025 financial results, highlighting $10.0 million in LOQTORZI net revenue, a 36% increase from Q1 2025. The company ended Q2 with $238 million in cash and completed the UDENYCA divestiture for $483.4 million, with potential milestone payments of up to $75 million.

Key pipeline developments include progress on CHS-114, a cytolytic CCR8 antibody, and casdozokitug, a first-in-class IL-27 antagonist, with data readouts expected in 1H 2026. The company reported a Q2 net loss from continuing operations of $44.9 million ($0.39 per share), while net income from discontinued operations was $342.6 million ($2.95 per share), primarily due to the UDENYCA divestiture gain.

Coherus Oncology (Nasdaq: CHRS) has scheduled its second quarter 2025 financial results release for August 7, 2025, after market close. The company will host a conference call and webcast at 5:00 p.m. EDT on the same day to discuss the results and provide a business update.

Investors can access the conference call through toll-free (800-715-9871) or international (646-307-1963) dial-in numbers using Conference ID 8712736. A live webcast and archived replay will be available on the company's investor relations website.

Coherus BioSciences (NASDAQ: CHRS) has rebranded as Coherus Oncology to reflect its strategic focus on innovative cancer immunotherapy treatments. The company is developing novel combination therapies centered around LOQTORZI® (toripalimab-tpzi), an FDA-approved PD-1 inhibitor for nasopharyngeal carcinoma. Their pipeline includes CHS-114, a selective CCR8 antibody targeting tumor regulatory T cells, and casdozokitug, a first-in-class IL-27 antagonist showing promise in various cancers. The company is backed by a distinguished Scientific Advisory Board and Board of Directors, featuring experts from leading institutions and organizations including the Cancer Research Institute, Merck, and Bristol Myers Squibb.

Coherus BioSciences (NASDAQ: CHRS) has announced a clinical collaboration with STORM Therapeutics to evaluate the combination of STC-15 (a METTL3 inhibitor) with LOQTORZI (toripalimab-tpzi), their next-generation PD-1 inhibitor. The first patient has been dosed in a Phase 1b/2 study targeting multiple cancer types including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, and endometrial cancer.

The study will enroll up to 188 patients in the United States, with Phase 1b focusing on safety and efficacy of the combination, followed by Phase 2 expansion cohorts. Under the agreement, Coherus will supply LOQTORZI while STORM will sponsor the trial, with both companies retaining commercial rights to their respective compounds.

Coherus BioSciences (CHRS) reported Q1 2025 financial results, highlighting its strategic transformation to innovative oncology. LOQTORZI generated net revenue of $7.3 million with >15% patient demand growth vs Q4 2024. The company completed the UDENYCA divestiture for up to $558.4 million, receiving $483.4 million upfront. Q1 results showed net loss from continuing operations of $47.4 million ($0.41/share). Key pipeline developments include positive Phase 1b data for CHS-114 in head and neck cancer and ongoing trials for casdozokitug combination therapy. Cash position was $82.4 million as of March 31, 2025. The company is advancing its oncology portfolio with LOQTORZI, the only FDA-approved treatment for nasopharyngeal carcinoma, while progressing clinical trials for CHS-114 and casdozokitug with data readouts expected in 2026.

Coherus BioSciences (NASDAQ: CHRS) has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025, after market close. The company will host a conference call and webcast at 5:00 p.m. EDT on the same day, where management will discuss the financial results and provide a business update. Investors can pre-register for the conference call to receive dial-in information and a personal PIN. A webcast will be available live and archived on the company's investor relations website. The Q1 2025 financial results press release and related materials will be accessible at https://investors.coherus.com before the conference call.

Coherus BioSciences (NASDAQ: CHRS) has announced its participation in four upcoming investor conferences in May and June 2025:

• Citizens Life Science Conference (May 8, NY)
• HCW BioConnect @ Nasdaq NYC 2025 (May 20, NY)
• TD Cowen 6th Annual Oncology Innovation Summit (May 27, Virtual)
• Jefferies Global Healthcare Conference (June 4, NY)

All presentations will be accessible via webcasts through the company's investor relations website, with replays available for 30 days. One-on-one meetings with management can be arranged through respective bank representatives.

Coherus BioSciences (NASDAQ: CHRS) presented promising Phase 1 clinical trial data for CHS-114, their selective anti-CCR8 antibody, in combination with toripalimab for head and neck squamous cell carcinoma (HNSCC) treatment at AACR 2025.

Key findings include:

• Confirmed partial response in a heavily pretreated PD-1 refractory patient
• >50% depletion in CCR8+ Treg cells
• Significant increase in CD8+ T cells
• Manageable safety profile consistent with advanced disease

The study evaluated CHS-114 as monotherapy and in combination with toripalimab in 21 patients with advanced solid tumors. A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing, with results expected in first half of 2026.